894852-01-8

Usage

Uses

Used in Organic Synthesis:
7-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE is used as a key intermediate in organic synthesis for the creation of various chemical compounds and molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 7-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE is used as a potential drug candidate for the development of new medications due to its unique structure and properties.
Used in the Development of Biologically Active Molecules:
7-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE is utilized as a building block in the synthesis of biologically active molecules, contributing to the advancement of drug discovery and therapeutic applications.

InChI:InChI=1S/C9H9BrN2O2/c1-9(2)8(13)12-7-6(14-9)3-5(10)4-11-7/h3-4H,1-2H3,(H,11,12,13)

Upstream product

• 600-00-0 ethyl 2-bromoisobutyrate 
• 20348-21-4 2,2-dimethyl-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 59154-46-0 ethyl ester of β-bromoisobutyric acid 
• 39903-01-0 2-amino-3-hydroxy-5-bromopyridine 

Relevant academic research and scientific papers

15-PGDH INHIBITOR

[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.

ALKYLIDINE SUBSTITUTED HETEROCYCLYL DERIVATIVES AS ANTI-BACTERIAL AGENTS

The present invention relates to alkylidine substituted heterocyclyl derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors; I in which P, Q, Ri, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed to antibacterial compounds

BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS

The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group